1. Home
  2. ZGN vs BEAM Comparison

ZGN vs BEAM Comparison

Compare ZGN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ermenegildo Zegna N.V.

ZGN

Ermenegildo Zegna N.V.

HOLD

Current Price

$11.88

Market Cap

2.4B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$31.19

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZGN
BEAM
Founded
1910
2017
Country
Italy
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.7B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
ZGN
BEAM
Price
$11.88
$31.19
Analyst Decision
Buy
Buy
Analyst Count
4
12
Target Price
$11.28
$50.75
AVG Volume (30 Days)
606.0K
2.0M
Earning Date
03-20-2026
05-06-2026
Dividend Yield
1.18%
N/A
EPS Growth
N/A
82.31
EPS
N/A
N/A
Revenue
N/A
$24,000.00
Revenue This Year
$5.17
N/A
Revenue Next Year
$7.89
$33.77
P/E Ratio
$25.94
N/A
Revenue Growth
N/A
33.33
52 Week Low
$7.61
$15.52
52 Week High
$12.40
$36.44

Technical Indicators

Market Signals
Indicator
ZGN
BEAM
Relative Strength Index (RSI) 60.63 60.08
Support Level $10.10 $22.24
Resistance Level $11.86 $32.01
Average True Range (ATR) 0.39 1.86
MACD 0.03 0.19
Stochastic Oscillator 77.37 82.38

Price Performance

Historical Comparison
ZGN
BEAM

About ZGN Ermenegildo Zegna N.V.

Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: